-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Kymera Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2019 to Q3 2024.
- Kymera Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$62.5M, a 18.2% decline year-over-year.
- Kymera Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$167M, a 0.01% decline year-over-year.
- Kymera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$147M, a 5.07% increase from 2022.
- Kymera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$155M, a 54.5% decline from 2021.
- Kymera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$100M, a 120% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)